SCHEMBL2945174

SCHEMBL2945174

CC(C)(C)OC(=O)N1CC(CN)(CC2CC2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.46
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
HPGD P15428 1/20 0.38
USP2 O75604 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
RECQL P46063 1/20 0.37
EPHX1 P07099 1/20 0.37
DDB1 Q16531 2/20 0.36
CRBN Q96SW2 2/20 0.36
KDM4E B2RXH2 1/20 0.36
PKM P14618 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
BACE1 P56817 2/20 0.35
CTSD P07339 1/20 0.35
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1820480 0.86 NR1H2 (0.43) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL15689694 0.80 NR1H2 (0.49) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL23070877 0.80 EPHX1 (0.47) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL30713542 0.78 NR1H2 (0.47) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL30722401 0.77 USP2 (0.37) NR1H2HPGDUSP2SMN1; SMN2EPHX1
SCHEMBL2943268 0.75 NR1H2 (0.44) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL1141357 0.74 USP2 (0.43) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL21906695 0.74 USP2 (0.43) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL27225356 0.74 USP2 (0.43) NR1H2HPGDUSP2SMN1; SMN2RECQL
SCHEMBL30713619 0.74 NR1H2 (0.43) NR1H2CHRM2CHRM1CHRM3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101084215-B Piperidine and azetidine derivatives as GLYT1 inhibitors MERCK SHARP & DOHME 2013-10-30 CN disclosed
EP-1831201-B1 PIPERIDINE AND AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS MERCK SHARP & DOHME (GB) 2010-08-04 EP disclosed
US-7655644-B2 Piperidine and azetidine derivatives as GlyT1 inhibitors MERCK SHARP & DOHME LIMITED (GB) 2010-02-02 US disclosed
US-20080090796-A1 Piperidine And Azetidine Derivatives As Glyt1 Inhibitors MERCK SHARP & DOHME (UK) LIMITED (GB) 2008-04-17 US disclosed
CN-101084215-A Piperidine and azetidine derivatives as GLYT1 inhibitors MERCK SHARP & DOHME (GB) 2007-12-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090796-A1 Piperidine And Azetidine Derivatives As Glyt1 Inhibitors SLC6A7, SLC1A1, SLC1A2 NR1H2 1583/4885CHRM2 742/4885CHRM1 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.